Chemo-free treatment for older women with node-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a chemotherapy-free approach for women age 65 and older with a common type of breast cancer (ER-positive, HER2-negative) that has spread to lymph nodes. Instead of chemotherapy, you would receive an oral targeted therapy (CDK4/6 inhibitor) after surgery to see if it can prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Female and 65 years or older
- ER-positive (estrogen receptor) breast cancer that is HER2-negative
- Cancer has spread to at least 1 lymph node (with certain high-risk features if fewer than 4 nodes)
- Have not had any chemotherapy or other cancer treatment before your surgery
- Willing to take a CDK4/6 inhibitor pill after surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stronger treatment (a CDK4/6 inhibitor) combined with less chemotherapy for early-stage breast cancer that is positive for hormone receptors and HER2. It aims to see if this approach works well while reducing side effects from chemo.
This trial tests whether it is safe to skip chemotherapy after surgery for certain patients with early-stage, hormone-receptor positive, HER2-negative breast cancer that has not spread to lymph nodes. Instead, they would receive hormone therapy plus a targeted CDK4/6 inhibitor (a pill that blocks cancer cell growth).
This trial tests whether skipping chemotherapy is safe for women with a specific type of early-stage breast cancer (ER-positive, HER2-negative) that has spread to 1–3 lymph nodes. Instead of chemo, you would receive a targeted pill called abemaciclib after standard hormone therapy.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This trial tests a combination of three anti-HER2 drugs plus a CDK4/6 inhibitor before surgery for women with a type of breast cancer that is both HER2-positive and ER-positive. It aims to see if this treatment can shrink tumors more effectively before surgery.
This trial tests whether older women with very low-risk, hormone-positive breast cancer can safely skip endocrine therapy (hormone-blocking pills) and radiation after lumpectomy. It aims to maintain quality of life while keeping cancer from coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.